Urgent Alert: 8,300% Spike in Colon Cancer Reports & Clinicians Report Cancers in Children – VAERS PRR 11.5 Demands Investigation . . .

Via Camus - October 16, 2025

A shocking analysis of the VAERS database by researcher Dr. Jessica Rose has uncovered a signal so significant it cannot be ignored. The focus: a dramatic surge in reports of colon cancer following the COVID-19 vaccine rollout.

It is critical to understand this is an analysis of reported adverse events, not a confirmed diagnosis of causation. However, the signal itself is staggering:

• An 8,300% increase in reports where colon cancer was listed as an adverse event in VAERS (2021-2023) compared to the previous three-year period (2018-2020).

• The Proportional Reporting Ratio (PRR), a key pharmacovigilance metric used to detect safety signals, is 11.5. A PRR over 2 is considered a definitive signal warranting an immediate causality assessment.

This is a five-alarm fire in our public health surveillance system. VAERS is designed precisely for this—to detect early warning signals that demand further investigation.

This signal, combined with the recent, concerning case of a sequenced colon cancer tumor found to contain plasmid DNA, points to a potential crisis that must be proactively addressed.

When leading clinicians report seeing 8, 9, and 10-year-olds with colon cancer—a previously unheard-of phenomenon—and a 13-year-old dies of metastatic pancreatic cancer, we must listen. The system is flashing red.

The call to action is clear and urgent:

1. Immediately launch large-scale sequencing of tumors in individuals with sudden-onset cancers post-vaccination.

2. Formally investigate the potential causal link suggested by this overwhelming VAERS signal.

The purpose of pharmacovigilance is to . . .

[SNIP]